<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="retraction" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1530358</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2024.1530358</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Retraction</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Retraction: CXCL6 promotes renal interstitial fibrosis in diabetic nephropathy by activating JAK/STAT3 signaling pathway</article-title>
<alt-title alt-title-type="left-running-head">Frontiers Editorial Office</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2024.1530358">10.3389/fphar.2024.1530358</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<collab>Frontiers Editorial Office</collab>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/228891/overview"/>
</contrib>
</contrib-group>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Approved by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/459226/overview">Giuseppe Remuzzi</ext-link>, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Italy</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Frontiers Editorial Office, <email>research.integrity@frontiersin.org</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>05</day>
<month>12</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1530358</elocation-id>
<history>
<date date-type="received">
<day>18</day>
<month>11</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>25</day>
<month>11</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Frontiers Editorial Office.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Frontiers Editorial Office</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<related-article id="RA1" related-article-type="retracted-article" journal-id="Front. Pharmacol." journal-id-type="nlm-ta" xlink:href="10.3389/fphar.2019.00224" ext-link-type="doi">A Retraction of the Original Research Article <article-title>CXCL6 promotes renal interstitial fibrosis in diabetic nephropathy by activating JAK/STAT3 signaling pathway</article-title> by Sun M-Y, Wang S-J, Li X-Q, Shen Y-L, Lu J-R, Tian X-H, Rahman K, Zhang L-J, Nian H and Zhang H (2019). Front. Pharmacol. 10:224. doi: <object-id>10.3389/fphar.2019.00224</object-id>
</related-article>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Renal Pharmacology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>The journal retracts the 25 March 2019 article cited above.</p>
<p>Following publication, concerns were raised regarding the integrity of the images in the published figures. Image duplication concerns were identified in Figure 6C. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers&#x2019; policies. As a result, the data and conclusions of the article have been deemed unreliable and the article has been retracted.</p>
<p>This retraction was approved by the Chief Editors of Frontiers in Pharmacology and the Chief Executive Editor of Frontiers. The authors agree to this retraction.</p>
</body>
</article>